Objectives-Regimens containing protease inhibitors (PI) are less commonly used in developing countries due to high cost and less availability. We evaluated characteristics of patients initiating PI-based therapy according to previous antiretroviral (ARV) exposure; factors associated with initiating a PI-containing regimen using newer versus older PIs, and proportion of patients with detectable viral loads (VL) after initiating a PI-based regimen.
Introduction
Antiretroviral therapy (ART) has been associated with improved morbidity and mortality among persons with human immune deficiency Virus (HIV) infection (Palella et al., 2006) . Currently 3 million patients have started taking first line ART in resource-limited settings (RLS). However, a significant proportion of patients fail first line ART for various reasons, particularly non-adherence (Gardner et al., 2008; Ramadhani et al., 2007) . As treatment cohorts mature, the need for second line protease inhibitor (PI) based regimens will increase.
There is very limited information on the use of PIs in RLS (Pujades-Rodriguez et al., 2008). Protease inhibitors are more expensive than first line NNRTI based regimen, thus limiting their use. Thus the characteristics of patients initiating PIs may be dictated more by access and affordability in RLS. Use of PIs has also been associated with toxicities, particularly metabolic. We explored characteristics of patients initiating PI based regimens, factors associated with use of newer versus older PIs and effectiveness of PI-based regimes in RLS amongst a large cohort of patients from the Asia-Pacific region.
Methods The Cohort
TREAT Asia HIV Observational Database (TAHOD) is a collaborative observational cohort study, currently involving 17 participating clinical sites across the Asia-Pacific region. Each site has recruited approximately 200 patients and collected demographic, and clinical data such as antiretroviral treatment, AIDS diagnosis, CD4 counts, viral load and other clinical and laboratory data. The nature and characteristics of the cohort have been described elsewhere . Ethics approval for the study was obtained from the University of New South Wales Ethics committee and the local ethics committee of each participating TAHOD site.
Inclusion Criteria
Data from PI initiation up to September 2007 were included in these analyses.
For the analysis of predictors for and effectiveness of PI-based therapy, all patients who initiated a PI were included and were categorised by previous ART exposure; naïve, first switch, second switch, third or greater switch; a switch was defined as starting or stopping any component of the ART regimen. For the analysis of factors associated with using older versus newer PIs, patients were included if they initiated their first PI therapy after 2000. Newer PIs were defined as those that were approved by the United States Food and Drug Administration (FDA) after 1 January 2000; these include lopinavir/ritonavir, atazanavir, amprenavir, fos-amprenavir, tipranavir and darunavir.
Measurements
The measurement closest to the date prior to PI initiation was used for baseline CD4 count, viral load and lipid laboratory results. Measurements were considered within the time window of 90 days before the date of starting the PI and up to 14 days after initiation. For the 6 and 12 month nominal visit times, a time window within +/− 3 months of the nominal visit time was adopted.
Statistics
Descriptive statistics were used to summarise characteristics of patients at PI initiation. Variables included country income (low, lower-middle, upper-middle and high income) as defined by the World Bank, generic or patent PIs, boosted RTV versus non-boosted RTV, older versus newer PIs, CD4 count, viral load and duration from HIV diagnosis to PI initiation.
Logistic regression was used to determine factors associated with initiating PI therapy using newer versus older PIs. Variables included in this analysis were prior ART exposure (naïve versus 1 st switch, 2 nd switch and 3 rd + switch), country income (high versus other income), RTV dose, generic versus patent PI, CD4 and viral load at PI initiation, and duration from HIV diagnosis to PI initiation.
Characteristics of patients with detectable and undetectable viral load (</>400 copies/ml) at 12 months were summarised at baseline, 6 months and at 12 months. Variables summarised included CD4, viral load, cholesterol, HDL-cholesterol, triglycerides and glucose. Logistic regression was used to determine factors associated with detectable viral load at 12 months. Patients who started PI and had viral load measurement at 12 months were included in this analysis. Factors included in the univariate models were prior ART exposure, country income, generic versus patent PI, CD4 and viral load at PI initiation, clinical adverse events at 12 month, duration from HIV diagnosis to PI initiation and duration of prior ART.
Multivariate analyses were performed using a forward stepwise approach. Variables with p< 0.10 in univariate analyses were considered for inclusion in multivariate analyses. All statistical analyses were performed using STATA 10.0 software, and all p-values were twosided. A level of significance at 0.05 was used throughout these analyses.
Results

Patient Characteristics
Of 3,821 patients in the TAHOD database, 1,102 initiated PI containing regimens; 612 of these were naive at PI initiation. Characteristics of the patients are described in Table 1 . Six hundred forty-seven patients (58.7%) were from high income countries. The majority of patients (63%) used patented PIs rather than generic. Median (IQR) of CD4 cells count at baseline was 134 (38.5 -242.5) cells/μL and median (IQR) of log 10 HIV-RNA was 4.7 (4.0 -5.3) copies/mL. Median time to first PI use from first HIV diagnosis was 1.3 (0.2 -3.7) years.
Indinavir was the most commonly used PI (48%) and ritonavir-boosted regimens were used by 53.6% (Table 2 ). Treatment failure was the main reason for experienced patients to switch to a PI-based regimen (26%), while adverse events were reported as the reason in 15.7% of patients who switched to a PI based regimen (Table 3) . Table 4 shows factors associated with patients using newer PIs. In the univariate analyses, factors related to the use of newer PI were: naive at PI initiation (p < 0.001), high income countries (p < 0.001), use of a patent PI (p < 0.001), CD4 200 -350 cells/μL at PI initiation (p = 0.01), viral load more than 50,000 copies/mL at PI initiation (p = 0.002) and longer duration from HIV diagnosis to PI initiation (p = 0.03).
Predictive Factors for Patients using a Newer PI (FDA approval after 2000)
Multivariate analysis showed that patients with prior ART exposure were less likely to use a newer PI compared with naive patients ( Table 5 summarises factors associated with having an undetectable VL at 12 months after starting PIs. Ninety per cent of patients had a detectable viral load at PI initiation and 74.3% achieved an undetectable viral load 12 months after starting PI-based therapy. Patients who had undetectable viral load at 12 months had a higher median CD4 count (162, range 50-264) compared to those with detectable viral loads at 12 months (96, range 31-182). Table 6 shows predictive factors of detectable viral loads at 12 months. In univariate analyses, factors associated with detectable viral loads were; use of PI in a second or subsequent PI regimen (p = 0.003), and CD4 200 -350 cells/μL at PI initiation (p < 0.031). In the multivariate analysis when adjusted for both the ARV regimen in which a PI was first used and CD4 at PI initiation only CD4 at PI initiation remained statistically significant to predict detectable viral load at 12 months (Table 6) .
Characteristics of Patients at Time of PI Initiation
Predictive Factors of Detectable Viral Loads at 12 Months
As a sensitivity analysis, we also conducted separate analyses for naive and experienced patients. For naive patients, the only predictor of detectable viral load at 12 months was a lower CD4 at PI initiation and it was similar to overall results. For experienced patients, the predictor of detectable viral loads at 12 months was being from a high income country (data not shown).
Discussion
We have described here the experience of PI use in a large cohort of patients in the AsiaPacific region. Of the total cohort initiating PIs, almost 50% used it in first line regimens. Using PI-based regimens for naïve patients was more common in high-income countries, and patients had access to ART earlier in the course of disease. More common use of patented PIs over generic PIs may be due to later availability of the generic PIs and patent protection in higher income countries. Use of generic PIs is expected to increase as these drugs become widely available. Currently, saquinavir, indinavir, ritonavir (including the heat stable formulation), lopinavir/ritonavir (heat stable formulation), and atazanavir are available in generic formulations. Indinavir (IDV) is the most commonly prescribed PI in this cohort, possibly because it was one of first PIs to become available in patented and generic versions. The effectiveness of IDV-based regimens has been documented in RLS. Studies have reported the effectiveness and lower toxicity rates in using a lower dose of indinavir, using the favourable pharmacokinetic effects of ritonavir boosting. (Duvivier et al., 2003; Mootsikapun et al., 2005) . However, the use of indinavir may decline as more potent and less toxic alternative PIs become increasingly accessible.
Although newer PIs retain effectiveness in patients with some PI resistance (Hicks et al., 2006; Pellegrin et al., 2008) , they are used as first line therapy and not just for second-line and salvage ART regimens in high income countries within TAHOD. However, when used for virologic failure, resistance testing would be useful to determine the potential effectiveness of these drugs. Studies indicate that darunavir is non-inferior to lopinavir/ ritonavir in naive patients, and may even be superior in those with high baseline viral loads (Ortiz et al., 2008) . Newer PIs also provide survival benefit as compared to use of older PIs (Crane et al., 2007) . Lack of access to these PIs may have contributed to patients continuing on a failing PI based regimens or switches between older PIs. This results in poor virologic suppression rates. Improved access to these drugs is urgently needed to better optimize the use of PIs in naive and treatment experienced patients in RLS.
Treatment failure was the most common reason for switching to a PI based regimen among ART experienced patients. PI based regimens are robust and have been proposed to be effective second line regimens after failing first line NNRTI-based regimens (Gallant, 2007; Martinez-Cajas and Wainberg, 2008) . This is especially true if failure has been identified early (by virologic rather than immunologic or clinical criteria). Patients in TAHOD who switched because of failure had lower CD4 counts (all <200/mm 3 ) reflecting late identification and treatment of failure, largely due to limited access to viral load testing and problems with affordability of PI therapy. Adverse events to NNRTI based regimens also led to substitution with PIs. Using PIs is the only option in patients with serious adverse events associated with use of both the first generation NNRTIs (Nevirapine and Efavirenz).
In spite of the limitations discussed above. PI based regimens including atazanavir, lopinavir, indinavir and other PIs had excellent virologic suppression rates at 12 months post initiation. This indicates the robustness of the PI or PI/r that significantly contributes to the overall regimen effectiveness. This is especially true when the backbone nucleosides are usually recycled and chosen without performing resistance testing. Protease inhibitors are highly potent drugs and have even shown to be effective as monotherapy in certain situations ( ). There may be variations in the evolution of resistance amongst various subtypes (Cavalcanti et al., 2007) . This calls for improving on the current protocols for identifying failures in ARV programs, particularly improved access to viral load testing. Availability of routine viral load testing may have contributed to more failures being reported from high income countries on PI based regimens in this cohort.
Apart from being an observational design, there are numerous limitations that need to be kept in mind. Since this cohort was established six years ago, the choice of PIs seems to reflect the availability at that point of time. As the cohort matures, use of newer PIs may increase. The sites contributing to data are heterogeneous with different accessibility issues (for drugs and monitoring), patient populations and clinical practices. Information on adherence is not routinely collected in this cohort which may have an impact on the effectiveness of PI-based regimens. The challenges associated with adhering to PI based regimens are much greater than with NNRTI based regimens, many of which have fixeddose formulations available. We have limited toxicity data, particularly information on metabolic parameters are not uniformly collected at various time points, thus making it difficult to analyse and conclude the safety of PI based regimens in these settings.
In summary, use of PIs in this cohort is affected by accessibility and affordability issues, particularly for the newer PIs. There is an urgent need to improve access to these drugs as the number of patients needing second line PI-based regimens is expected to increase in the near future. PI based regimens are effective in these settings but increased resources for virological monitoring are also needed to optimise effectiveness through earlier identification of failure. Table 1 Baseline characteristics of patients starting PIs. NB: PI naïve is patients used a PI as their first treatment, 1 st switch is when patients first included PI in their second regimen, Table 2 Distribution of first PI drugs used in TAHOD.
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